CTOs on the Move

Sanofi Genzyme

www.sanofigenzyme.com

 
Sanofi Genzyme, the specialty care business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

westwood laboratories

westwood laboratories is a Azusa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abivax

Abivax is a clinical stage biopharmaceutical company that focuses on developing treatments for inflammatory diseases, viral infections, and cancer by modulating the bodys natural immune system machinery.

JASPER CLINICAL RandD INC

JASPER CLINICAL R&D INC is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Texas Road Pharmacy

Texas Road Pharmacy is a Monroe Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ionis Pharmaceuticals

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.